Drug
Olmutinib clinical trials
Also written HM61713.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 1
Hanmi Pharmaceutical Company Limited (5) · Konkuk University Medical Center (1) · Boehringer Ingelheim (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
- One of Tyrosine Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses olmutinib is read from its arms, and is right about nine times in ten.
Testing it · 7
- Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the LungTerminatedPhase 2Hanmi Pharmaceutical Company LimitedNCT02485652Written as HM61713
- Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKITerminatedPhase 1Hanmi Pharmaceutical Company LimitedNCT04510415Written as Olmutinib
- Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNACompletedPhase 2Konkuk University Medical CenterNCT03228277Written as Olmutinib
- Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer TherapyCompletedPhase 2Hanmi Pharmaceutical Company LimitedNCT02444819Written as HM61713
- Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC PatientsCompletedPhase 1/2Hanmi Pharmaceutical Company LimitedNCT01588145Written as HM61713
- Study to Evaluate a Pharmacokinetic of HM61713 in Healthy Male SubjectsCompletedPhase 1Hanmi Pharmaceutical Company LimitedNCT01894399Written as HM61713
- Olmutinib (BI 1482694) ADME StudyCompletedPhase 1Boehringer IngelheimNCT02722161Written as [14C]BI 1482694
Codes
What other systems call olmutinib · ClinicalTrials.gg INT000657
- MeSH (NLM) C000617753olmutinibOne source NLM
- UNII (FDA) CHL9B67L95OLMUTINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27088175olmutinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C101791OlmutinibOne source FDA
- DrugBank DB13164One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000617753 | olmutinib | One source NLM |
| UNII (FDA) | CHL9B67L95 | OLMUTINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27088175 | olmutinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C101791 | Olmutinib | One source FDA |
| DrugBank | DB13164 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.